A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.

MLA

Paquet, Eric R., et al. “A 12-Gene Signature to Distinguish Colon Cancer Patients with Better Clinical Outcome Following Treatment with 5-Fluorouracil or FOLFIRI.” The Journal of Pathology. Clinical Research, vol. 1, no. 3, Apr. 2015, pp. 160–72. EBSCOhost, https://doi.org/10.1002/cjp2.17.

APA

Paquet, E. R., Cui, J., Davidson, D., Pietrosemoli, N., Hassan, H. H., Tsofack, S. P., Maltais, A., Hallett, M. T., Delorenzi, M., Batist, G., Aloyz, R., & Lebel, M. (2015). A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. The Journal of Pathology. Clinical Research, 1(3), 160–172. https://doi.org/10.1002/cjp2.17

Chicago

Paquet, Eric R, Jing Cui, David Davidson, Natalia Pietrosemoli, Houssein Hajj Hassan, Serges P Tsofack, Annie Maltais, et al. 2015. “A 12-Gene Signature to Distinguish Colon Cancer Patients with Better Clinical Outcome Following Treatment with 5-Fluorouracil or FOLFIRI.” The Journal of Pathology. Clinical Research 1 (3): 160–72. doi:10.1002/cjp2.17.